ACADIA Pharmaceuticals ( NASDAQ:ACAD – Get Rating ) had its price target raised by stock analysts at Cantor Fitzgerald from $28.00 to $33.00 in a report issued on Tuesday, The Fly reports. The brokerage presently has an 'overweight' rating on the biopharmaceutical company's stock. Cantor Fitzgerald's target price indicates a potential upside of 67.77% from the stock's current price. A number of other analysts also recently issued reports on the stock. Citigroup lifted their price objective on shares of ACADIA Pharmaceuticals from $19.

https://www.dailypolitical.com/2023/03/16/cantor-fitzgerald-increases-acadia-pharmaceuticals-nasdaqacad-price-target-to-33-00.html

#dailypolitical